(CercleFinance.com) – Novo Nordisk on Monday unveiled more detailed results from its trial on the cardiovascular benefits of its anti-obesity drug Wegovy, which caused a stir this summer.
The Danish laboratory indicated in August that semaglutide 2.4 mg (Wegovy) had reduced the risk of a major cardiovascular event by 20% over a period of five years.
This announcement allowed it to reach historic highs on the stock market and steal from LVMH the position of largest market capitalization in Europe.
According to Novo, the first findings of this phase III trial, called ‘Select’, show that this 20% level was statistically significantly independent of age, gender, ethnicity and index body mass of the participants.
These results also show that the beneficial effects in terms of reducing the risk of major cardiovascular events were evident from the start of treatment, which suggests a faster effect than expected.
These initial conclusions were revealed during the American Heart Association congress and published at the same time in the New England Journal of Medicine.
Following these announcements, Novo Nordisk shares rose by more than 3% on Monday on the Copenhagen Stock Exchange.
Copyright (c) 2023 CercleFinance.com. All rights reserved.